Sabatolimab (MBG453), a humanized IgG4 (S228P) antibody targeting TIM-3, is a potent inhibitory receptor that regulates adaptive and innate immune responses.

Kutkoside is a mixture of iridoid glycosides namely, picroside II, Picroside IV and 6-ferulloylcatalpol, it may have antinociceptive and anti-inflammatory effects.

(+)-Epiaschantin shows marginal cancer cell line inhibitory activities. It also has anti-platelet aggregation activity.